股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年5月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 | RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 | RMB | ...

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - The company's Q1 2025 revenue of 3.099 billion yuan represents a year-on-year growth of 16.03%, with a net profit attributable to shareholders of 306 million yuan, up 32.54% year-on-year [1][2]. - The report indicates that the company's revenue is in line with market expectations, and future performance is expected to show gradual quarter-on-quarter improvement [2]. - The company has adjusted its revenue forecasts for 2025-2027, with expected revenues of 14.077 billion yuan, 16.473 billion yuan, and 19.528 billion yuan, respectively [3]. Summary by Sections Financial Performance - In Q1 2025, the laboratory business generated 1.857 billion yuan in revenue, a 15.7% increase year-on-year, while the CMC business saw revenue of 693 million yuan, up 19.1% [2]. - The adjusted net profit for Q1 2025 was 349 million yuan, reflecting a 3.14% increase year-on-year [1][2]. - The gross margins for the laboratory and CMC businesses improved to 45.54% and 30.44%, respectively, with year-on-year increases of 140 basis points and 254 basis points [2]. Future Outlook - The company anticipates a continued upward trend in performance, supported by a rapid increase in new orders, which grew over 10% year-on-year in Q1 2025 [2]. - The company maintains its revenue guidance for 2025 at a growth rate of 10% to 15% [2]. Valuation and Earnings Forecast - The report adjusts the earnings per share (EPS) forecasts for 2025-2027 to 0.98 yuan, 1.22 yuan, and 1.54 yuan, respectively, with corresponding price-to-earnings (PE) ratios of 24, 19, and 15 times based on the closing price of 23.52 yuan per share on April 29, 2025 [3][8].

Investment Rating - The investment rating for the company is "Outperform" (maintained) [2] Core Insights - The company reported a strong recovery in Q1 2025, with revenue and profit both achieving double-digit growth. Q1 revenue reached 3.099 billion, a year-on-year increase of 16.03%, while net profit attributable to shareholders was 306 million, up 32.54% year-on-year [4][6] - All major business segments experienced growth, with laboratory services revenue at 1.857 billion (up 15.74% year-on-year) and a gross margin increase to 45.54%. CMC (small molecule CDMO) services revenue was 693 million (up 19.05% year-on-year) with a significant gross margin improvement to 30.44% [7] - The company is seeing strong growth from European clients, with revenue from North America and Europe increasing by 16.81% and 26.57% year-on-year, respectively. Revenue from global top 20 pharmaceutical companies grew by 29.05% year-on-year [7] - New orders are accelerating, with Q1 2025 new orders up over 10% year-on-year, and the company maintains its full-year guidance of 10%-15% revenue growth for 2025 [7] Financial Data and Profit Forecast - The company forecasts total revenue of 13.795 billion for 2025, with a year-on-year growth rate of 12.4%. The net profit attributable to shareholders is projected to be 1.819 billion, reflecting a growth rate of 1.4% [6][9] - The earnings per share (EPS) is expected to be 1.02 for 2025, with a gross margin forecasted to improve to 35.8% [6] - The return on equity (ROE) is projected to be 12.1% for 2025, with corresponding price-to-earnings (PE) ratios of 23, 20, and 17 for the years 2025, 2026, and 2027, respectively [6][7]

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [3][7]. Core Views - The company has shown consistent growth in laboratory services over the past five quarters, with a significant increase in new orders, particularly in the CMC segment, indicating a positive outlook for revenue growth [7]. - The company expects a revenue growth of 10-15% for the full year 2025, supported by strong order trends and the gradual realization of CMC business [7]. - The financial projections for 2025-2027 indicate a steady increase in revenue and net profit, with expected revenues of 137 billion, 155 billion, and 179 billion respectively, and net profits of 19 billion, 22 billion, and 26 billion [7][10]. Financial Data and Valuation - For 2025, the company is projected to achieve total revenue of 137.46 billion, with a year-on-year growth of 12% [2]. - The adjusted net profit for 2025 is estimated at 18.56 billion, reflecting a 16% increase compared to the previous year [2][10]. - The earnings per share (EPS) for 2025 is projected to be 1.07, with a price-to-earnings (PE) ratio of 20.5 [2][11]. Revenue Breakdown - Laboratory services revenue for Q1 2025 reached 18.6 billion, showing a year-on-year growth of 15.7% [7]. - The CMC segment generated 6.9 billion in revenue for Q1 2025, with a year-on-year increase of 19.1% [7]. - Clinical research services reported revenue of 4.5 billion in Q1 2025, reflecting a year-on-year growth of 14.2% [7]. Shareholder Information - The total market capitalization of the company is approximately 41.4 billion, with a circulating market value of 33 billion [3]. - The major shareholder holds a 14.07% stake in the company [3]. Financial Ratios - The company’s return on equity (ROE) stands at 13.3%, with a debt-to-asset ratio of 39.8% [3][11]. - The projected net profit margin for 2025 is 13.8%, indicating a stable profitability outlook [11].

Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 3.099 billion CNY, a year-on-year increase of 16% [2] - The net profit attributable to shareholders was 306 million CNY, reflecting a growth of 32.5% year-on-year [2] - Adjusted net profit was 349 million CNY, with a year-on-year growth rate of 3.1%, which is slower than revenue growth [2] Group 2: Business Segment Performance - Laboratory services generated revenue of 1.857 billion CNY, up 15.7% year-on-year, with a gross margin of 45.5%, an increase of 1.4 percentage points [4] - CMC (small molecule CDMO) services reported revenue of 693 million CNY, a growth of 19.1%, with a gross margin of 30.4%, up 2.5 percentage points [4] - Clinical research services achieved revenue of 447 million CNY, marking a 14.2% increase [4] - Revenue from large molecule and cell & gene therapy services was 99 million CNY, reflecting a growth of 7.9% [4] Group 3: Operational Insights - The strong operating cash flow reached 853 million CNY, a year-on-year increase [2] - The company’s workforce increased compared to the same period in 2024 due to new hires [2] - The second phase of the small molecule CDMO in Shaoxing is under construction, with two workshops expected to be operational by the end of 2025 [6] Group 4: Market Dynamics - Over 90% of the small molecule CDMO business comes from overseas clients, indicating a strong international market presence [7] - The company’s laboratory chemical services are expanding in scope, driven by industry recovery and new technology developments [5]

Financial Performance - In Q1 2025, the Company reported revenue of RMB 2,671 million, a decrease of 16.0% compared to RMB 3,099 million in Q1 2024 [10] - Net profit for Q1 2025 was RMB 231 million, down 32.5% from RMB 306 million in Q1 2024 [10] - Non-IFRS net profit slightly decreased by 3.1% to RMB 339 million from RMB 349 million in Q1 2024 [10] - Net operating cash flow was RMB 746 million, a decline of 14.4% from RMB 853 million in Q1 2024 [10] Revenue Composition - Revenue from China entities accounted for 88%, while overseas subsidiaries contributed 12% [12] - Laboratory services generated 60% of total revenue, followed by small molecule CDMO services at 22%, and clinical development services at 14% [12] - Revenue from the top 20 pharmaceutical customers grew by 29.1%, while revenue from other customers increased by 14.0% [12] Growth Rates - New purchase orders (POs) achieved over 10% year-on-year growth in Q1 2025 [10] - Revenue from China entities grew by 15.7%, while overseas subsidiaries saw an 18.3% increase [12] - North America revenue increased by 16.8%, and EU revenue grew by 26.6% [12] Cost and Margin Analysis - Gross margin for laboratory services improved to 45.5% in Q1 2025 from 44.1% in Q1 2024, reflecting a 1.4 percentage point increase [14] - Gross margin for small molecule CDMO services rose to 30.4%, up 2.5 percentage points from 27.9% in Q1 2024 [15] - Clinical development services in China achieved a gross margin of 11.8%, an increase of 2.5 percentage points from 9.3% in Q1 2024 [16] Future Outlook - The Company maintains a revenue growth guidance of 10-15% for 2025 [27] - Despite macroeconomic uncertainties, the Company believes in sustained industry development driven by healthcare demands and technological innovations [27]

Financial Performance - Revenue for Q1 2025 reached RMB 3,099 million, a 16.0% increase from RMB 2,671 million in Q1 2024 [9] - Net profit attributable to shareholders was RMB 306 million, up 32.5% from RMB 231 million in Q1 2024 [9] - Non-IFRS adjusted net profit increased by 3.1% to RMB 349 million from RMB 339 million [9] - Operating cash flow for Q1 2025 was RMB 853 million, a 14.4% increase from RMB 746 million in Q1 2024 [9] Revenue Composition - Revenue from China delivery business grew by 15.7% [11] - Revenue from overseas delivery business increased by 18.3% [11] - Laboratory services contributed 60% to revenue, with clinical research services at 14% and CDMO at 22% [11] - Revenue from top 20 pharmaceutical companies grew by 29.1% [14] Customer Growth - Revenue from North American clients increased by 16.8% [12] - Revenue from European clients rose by 26.6% [12] - Revenue from Chinese clients grew by 13.1% [12] Cost and Margin Analysis - Gross margin for laboratory services improved to 45.5% in Q1 2025 from 44.1% in Q1 2024 [17] - Gross margin for clinical services increased to 11.8% from 9.3% [19] - Gross margin for large molecule services improved despite being in a construction phase [20] Strategic Outlook - The company aims for a revenue growth target of 10-15% for the full year 2025 [33] - The company emphasizes the importance of health demand and technological innovation in driving industry growth [33]

Core Viewpoint - 康龙化成 has shown strong growth in new orders and continues to enhance its global presence, leading to a positive outlook for the company [1][2]. Financial Performance - In Q1 2025, 康龙化成 achieved revenue of 30.99 billion yuan, a year-on-year increase of 16.03% - The net profit attributable to shareholders was 3.06 billion yuan, up 32.54% year-on-year, while the net profit excluding non-recurring items was 2.92 billion yuan, reflecting a 56.08% increase year-on-year [2]. - The gross margin for Q1 2025 was 66.34%, showing a year-on-year decrease of 1.01 percentage points but a quarter-on-quarter increase of 1.51 percentage points [2]. Business Segments - New orders increased by over 10% year-on-year, with laboratory services and CMC (small molecule CDMO) services both seeing significant growth [3]. - Revenue by segment includes: - Laboratory services: 18.57 billion yuan, up 15.74% year-on-year - CMC (small molecule CDMO) services: 6.93 billion yuan, up 19.05% year-on-year - Clinical research services: 4.47 billion yuan, up 14.25% year-on-year - Large molecule and cell & gene therapy services: 9.87 billion yuan, up 7.94% year-on-year [3]. Investment Outlook - The company is expected to generate revenues of 137.15 billion yuan, 155.39 billion yuan, and 173.88 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 11.7%, 13.3%, and 11.9% [4]. - The net profit forecasts for the same years are 17.56 billion yuan, 21.77 billion yuan, and 24.71 billion yuan, with corresponding price-to-earnings ratios of 24, 19, and 17 [4].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expected stock price increase of over 15% relative to the benchmark index within the next 12 months [4][10]. Core Insights - The company achieved a revenue of 3.099 billion yuan in Q1 2025, representing a year-on-year increase of 16.03%, and a net profit attributable to shareholders of 306 million yuan, up 32.54% year-on-year [1][2]. - The company continues to strengthen its technological advantages in small molecule research and production services, establishing an integrated service platform that serves numerous global clients [3]. - New order growth exceeded 10% year-on-year in Q1 2025, with laboratory services and CMC (small molecule CDMO) services both showing strong performance [2]. Summary by Sections Financial Performance - In Q1 2025, domestic revenue grew by 15.71%, accounting for 87.74% of total revenue, while overseas revenue increased by 18.33%, making up 12.26% of total revenue [1]. - The gross margin for Q1 2025 was 66.34%, showing a year-on-year decrease of 1.01 percentage points but an increase of 1.51 percentage points from the previous quarter [1]. - The company expects revenues of 13.715 billion yuan, 15.539 billion yuan, and 17.388 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 11.7%, 13.3%, and 11.9% [3][5]. Business Segments - Revenue from laboratory services reached 1.857 billion yuan, up 15.74% year-on-year; CMC services generated 693 million yuan, up 19.05%; clinical research services brought in 447 million yuan, up 14.25%; and large molecule and cell and gene therapy services totaled 987 million yuan, up 7.94% [2]. Future Outlook - The company is projected to achieve net profits of 1.756 billion yuan, 2.177 billion yuan, and 2.471 billion yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 24, 19, and 17 [3][5].

Core Viewpoint - The company reported a slight revenue beat in Q1 2025, with adjusted Non-IFRS net profit slightly below expectations, primarily due to higher-than-expected losses from non-operating items [1] Revenue Performance - Q1 2025 revenue reached RMB 3.099 billion, representing a 16% year-over-year increase but a 10.4% quarter-over-quarter decline, slightly above expectations [1] - Laboratory services and clinical research services outperformed expectations, contributing to revenue growth [1][2] Segment Analysis - Laboratory services revenue grew by 15.7% YoY and 1.6% QoQ, with gross margin slightly improving by 1.4 percentage points YoY and 0.2 percentage points QoQ [2] - CMC services revenue increased by 19.1% YoY but decreased by 31.5% QoQ, with a gross margin improvement of 2.5 percentage points YoY [2] - Clinical research services revenue rose by 14.2% YoY and fell by 14% QoQ, with gross margin also improving by 2.5 percentage points YoY [2] - CGT revenue grew by 7.9% YoY and 2.2% QoQ, although gross margin declined significantly by 30.3 percentage points YoY due to increased operational and depreciation costs [2] Order Growth - Overall new orders in Q1 2025 achieved a growth rate of over 10% YoY, with CMC's backlog orders growing by over 20% YoY [3] - Management maintains a revenue guidance of 10%-15% growth for the full year 2025, despite a slowdown in new order growth compared to previous quarters [3] External Factors - The impact of tariffs on the company is limited, with minimal reliance on U.S. sourced materials, and the company is well-prepared with sufficient inventory [4] - The recovery of overseas biopharmaceutical financing remains slow, with only signs of moderate recovery in VC financing [4] Investment Rating - The company maintains a "Buy" rating, with target prices set at HKD 20 for Hong Kong shares and RMB 32 for A-shares, reflecting a premium of 80% for A-shares compared to Hong Kong shares [5]